Literature DB >> 11361055

Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis.

M Odeh1, A Oliven.   

Abstract

Desmopressin, a synthetic analogue of the antidiuretic hormone, is an effective medication for primary nocturnal enuresis for both children and adults. Its safety is well established. Although it has a favorable side effect profile, because of its pharmacological effect, intranasal desmopressin can rarely induce water intoxication with profound hyponatremia if given without adequate restriction of water intake. The authors describe an adult patient with water intoxication and severe hyponatremia accompanied by loss of consciousness and seizures after 2-day intranasal administration of desmopressin. The present and the previously reported cases emphasize the need for greater awareness of the development of this serious and potentiallyfatal complication. In addition, to adjust the drug to the lowest required dosage, adequate restriction of water intake is recommended, and serum levels of sodium should be measured periodically to allow for early detection of water intoxication and hyponatremia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11361055     DOI: 10.1177/00912700122010320

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Nephrolithiasis complicating treatment of diabetes insipidus.

Authors:  Saurabh Mehandru; David S Goldfarb
Journal:  Urol Res       Date:  2005-05-29

Review 2.  Pharmacological management of renal colic in the older patient.

Authors:  Blayne K Welk; Joel M H Teichman
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Comparative tolerability of drug treatment for nocturnal enuresis in children.

Authors:  Dominik Müller; Charles C Roehr; Paul Eggert
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.

Authors:  Henrik Agersø; Lotte Seiding Larsen; Anders Riis; Ulf Lövgren; Mats O Karlsson; Thomas Senderovitz
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.